University of Louisville homepage
All experts
All experts

Gunjan Garg

Assoc Professor Term

School of Medicine

Orcid identifier0009-0007-0672-6426
  • Assoc Professor Term
    School of Medicine

SPONSORED PROJECTS

  • Showing page 1 out of 1
Showing page 1, sponsored projects 1 to 10 of 10
GRANT
An Open-Label Study to Assess the Efficacy and Safety of Extended TARPEYO® (Delayed-Release Budesonide Capsules) Treatment in Adult Patients with Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO 16 mg Once Daily Treatment in Real-World Clinical Practice
Calliditas Therapeutics AB_CTAB1 Jan 2025
MORELEARN MORE
GRANT
AWD-00000109|Dimerix IQVIA DMX-200-301
Dimerix Biopharmaceutical Ltd_DBL1 Jan 2025 - 31 Dec 2030
MORELEARN MORE
GRANT
240375|D3466C00001 - A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis
AstraZeneca_ASTRA3 Jan 2024
MORELEARN MORE
GRANT
240066|TVTX-RE021-204 A MC, Single-Group Ph 2, Exploratory, OL Study to Investigate Safety and Effect of Sparsentan in Combination W Sodium Glucose Cotransporter-2 (SGLT2) Ihibition in the Treatment of Adult Participants W/ Immunoglobulin A Nephropathy (IgAN)
Travere Therapeutics Inc_TRAVERETHER1 Jan 2023
MORELEARN MORE
GRANT
220688|CHK01-01 - A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function
IQVIA RDS Inc_IQVIA6 Mar 2022
MORELEARN MORE
GRANT
210676|ALXN1210-NEPH-202 -A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Syneos Health_SH1 Jan 2021
MORELEARN MORE
GRANT
200210|021FSGS16010-A Randomized,Multicenter,Double-Blind,Parallel,Active-Control Study Of The Effects Of Sparsentan, A Dual Endothelin Receptor And Angiotensin Receptor Blocker,On Renal Outcomes In Patients With Primary Focal Segmental Glomerulosclerosis(FSGS)
IQVIA RDS Inc_IQVIA3 Oct 2020 - 31 Dec 2026
MORELEARN MORE
GRANT
201109|021IGAN17001: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
IQVIA RDS Inc_IQVIA (SPN-000259)9 Jan 2020 - 31 Dec 2027
MORELEARN MORE
GRANT
180567|Nef-301-A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF NEFECON IN PATIENTS WITH PRIMARY IGA NEPHROPATHY AT RISK OF PROGRESSING TO END-STAGE RENAL DISEASE (NefIgArd)
Medpace Inc_MPI1 Jan 2019
MORELEARN MORE
GRANT
181065|AUR_VCS-2017-03 Phase 2 -- An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Parial Remission of Protein uria in Subjecs with Focal Segmental Glomerulosclerosis (Aurona)
Clinical Trial Services Inc_CTSI12 Jul 2018
MORELEARN MORE